PTPN11 and cancer: As predicted, in cancer cells carrying BRAFV600E, KRASG13D, or NRASQ61K mutations, treatment with up to 10 μM TNO155 or RMC-4550 showed little or no growth inhibition, thus validating the SHP2 independence of these cell lines (Figure 5B).